Q32 Bio (QTTB) Projected to Announce Quarterly Earnings on Wednesday

Q32 Bio (NASDAQ:QTTB) will likely be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $1.00 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Q32 Bio (NASDAQ:QTTB) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. On average, analysts expect Q32 Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Q32 Bio Price Performance

Q32 Bio stock opened at $15.16 on Tuesday. The firm has a market capitalization of $257.11 million, a P/E ratio of 5.70 and a beta of 0.23. Q32 Bio has a one year low of $1.57 and a one year high of $23.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.36 and a quick ratio of 5.36. The business has a fifty day moving average price of $13.48 and a 200-day moving average price of $8.16.

Insiders Place Their Bets

In other Q32 Bio news, Director Orbimed Advisors Llc purchased 1,875,000 shares of the stock in a transaction on Thursday, May 28th. The shares were purchased at an average price of $8.00 per share, with a total value of $15,000,000.00. Following the acquisition, the director directly owned 3,502,987 shares in the company, valued at approximately $28,023,896. The trade was a 115.17% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Diyong Xu purchased 1,875,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were acquired at an average price of $8.00 per share, with a total value of $15,000,000.00. Following the transaction, the director owned 3,502,987 shares in the company, valued at approximately $28,023,896. The trade was a 115.17% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 34.46% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. HRT Financial LP grew its position in Q32 Bio by 66.5% in the fourth quarter. HRT Financial LP now owns 24,698 shares of the company’s stock worth $81,000 after acquiring an additional 9,862 shares in the last quarter. Marshall Wace LLP bought a new position in Q32 Bio in the second quarter valued at $25,000. Geode Capital Management LLC raised its position in Q32 Bio by 19.9% during the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock valued at $352,000 after purchasing an additional 17,617 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in Q32 Bio during the fourth quarter valued at about $66,000. Finally, XTX Topco Ltd bought a new stake in Q32 Bio during the fourth quarter worth about $68,000. 31.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on QTTB shares. Weiss Ratings raised Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 11th. Mizuho began coverage on Q32 Bio in a research report on Friday, May 22nd. They set an “outperform” rating and a $14.00 price target on the stock. Zacks Research cut Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Cantor Fitzgerald assumed coverage on shares of Q32 Bio in a report on Monday, May 18th. They issued an “overweight” rating on the stock. Finally, Oppenheimer raised their price objective on shares of Q32 Bio from $20.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $30.00.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.